News stories about Jazz Pharmaceuticals (NASDAQ:JAZZ) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.6299093809835 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Analysts Issue Forecasts for Jazz Pharmaceuticals plc -‘s FY2022 Earnings (JAZZ) (americanbankingnews.com)
- ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632 (zacks.com)
- How Jazz’s Erwinaze, Defitelio, and Prialt Performed in 3Q17 (finance.yahoo.com)
- How Analysts Rated Jazz Pharmaceuticals in December (finance.yahoo.com)
- How Did Jazz Pharmaceuticals Perform in 3Q17? (finance.yahoo.com)
Jazz Pharmaceuticals (JAZZ) traded down $1.15 during trading on Friday, reaching $135.59. The company had a trading volume of 379,000 shares, compared to its average volume of 399,889. Jazz Pharmaceuticals has a fifty-two week low of $112.52 and a fifty-two week high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. The company has a market capitalization of $8,200.00, a PE ratio of 22.34, a P/E/G ratio of 0.76 and a beta of 0.97.
In other Jazz Pharmaceuticals news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.15, for a total transaction of $27,830.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $139.73, for a total transaction of $1,257,570.00. The disclosure for this sale can be found here. Insiders have sold 17,552 shares of company stock valued at $2,399,643 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.